North Carolina Headlines

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Oral Mucositis Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Oral Mucositis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Oral Mucositis Market

• The market size for Oral Mucositis in the leading markets is expected to grow significantly by 2036.

• The United States accounted for the highest Oral Mucositis treatment market size among the 7MM in 2025, compared to the EU4 countries, the United Kingdom, and Japan.

• According to DelveInsight’s estimates, the Oral Mucositis market is projected to increase from nearly USD 235 million in 2022 to approximately USD 600 million by 2036, reflecting the growing demand for effective supportive care therapies.

• According to Bell and Kasi (2023), patients receiving high-dose chemotherapy or bone marrow transplantation have approximately a 76% risk of developing Oral Mucositis.

• According to Pacheco et al. (2021), the overall incidence of Oral Mucositis among patients undergoing head and neck cancer treatment is approximately 89.4%, with mild, moderate, and severe Oral Mucositis accounting for 16.8%, 34.5%, and 26.4% of cases, respectively.

• According to Claudio et al. (2020), nearly 40% of patients receiving chemotherapy develop Oral Mucositis, while the incidence rises to almost 90% among head and neck cancer patients receiving combined chemotherapy and radiotherapy.

• Leading Oral Mucositis companies, such as OncoZenge, EpicentRx, Soligenix, 6S Pharma, Camurus, Amgen, Swedish Orphan Biovitrum, Access Pharmaceuticals, Aurora BioScience, and others, are developing innovative Oral Mucositis therapies that are expected to become available in the market during the forecast period.

• The promising Oral Mucositis therapies in clinical development include BupiZenge, Nibrozetone (RRx-001), Dusquetide (SGX942), 6SP-001, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/oral-mucositis-om-market

Key Factors Driving the Oral Mucositis Market

• Increasing Incidence of Cancer and Cancer Treatment: The growing prevalence of cancer worldwide and the increasing use of chemotherapy, radiotherapy, targeted therapies, and hematopoietic stem cell transplantation have significantly increased the number of patients at risk of developing Oral Mucositis. Since Oral Mucositis remains one of the most common dose-limiting toxicities associated with cancer treatment, demand for effective preventive and therapeutic options continues to increase.

• Growing Demand for Effective Supportive Care Therapies: Current management of Oral Mucositis mainly focuses on pain control, nutritional support, maintenance of oral hygiene, topical anesthetics, mucosal protectants, cytoprotectants, mouthwashes, and supportive care interventions. The absence of highly effective disease-specific therapies continues to drive research toward innovative treatment approaches.

• Increasing Development of Novel Therapies: Several pharmaceutical companies are actively developing innovative Oral Mucositis therapies with novel mechanisms of action. These therapies are expected to improve symptom management, reduce treatment-related complications, minimize treatment interruptions, and improve patients’ quality of life.

Oral Mucositis Competitive Landscape

Several Oral Mucositis therapies are currently under clinical development, including BupiZenge (OncoZenge), Nibrozetone (RRx-001) (EpicentRx), Dusquetide (SGX942) (Soligenix), and 6SP-001 (6S Pharma).

These investigational therapies utilize diverse mechanisms, including local anesthetic-based pain relief, NLRP3 inhibition with Nrf2 activation, innate defense regulation, anti-inflammatory activity, and tissue healing enhancement. Their successful development is expected to provide better efficacy and improved tolerability compared to existing supportive care therapies.

Discover more about therapies set to grab major Oral Mucositis market share @ Oral Mucositis Treatment Landscape

Recent Developments in the Oral Mucositis Market

• In January 2026, OncoZenge announced that the one-month stability study results for its BupiZenge lozenge technology batch were within specifications following successful manufacturing after technology transfer to Meribel Pharma Solutions.

• In December 2025, OncoZenge announced the submission of the Clinical Trial Application (CTA) for the pivotal Phase III BZ003 clinical trial evaluating BupiZenge.

• In March 2023, the US FDA granted Fast Track Designation to Nibrozetone (RRx-001) for the prevention and attenuation of severe Oral Mucositis associated with chemotherapy and radiation therapy in patients with head and neck cancer.

• Dusquetide (SGX942) has demonstrated encouraging efficacy and safety in Phase II and Phase III clinical studies involving patients with Oral Mucositis receiving chemoradiation therapy.

What is Oral Mucositis?

Oral Mucositis is a common and debilitating complication of chemotherapy, radiotherapy, targeted therapies, and hematopoietic stem cell transplantation. It is characterized by inflammation and ulceration of the oral mucosa, leading to severe pain, difficulty eating, swallowing, and speaking, increased susceptibility to infections, and interruption of cancer treatment. Current treatment primarily focuses on supportive care, including pain management, nutritional support, oral hygiene, topical agents, mucosal protectants, and preventive interventions, while several innovative therapies are being developed to improve patient outcomes.

Oral Mucositis Epidemiology Segmentation

The Oral Mucositis epidemiology section provides insights into the historical and current Oral Mucositis patient pool and forecasted trends for the leading markets. The Oral Mucositis market report provides epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Incident Cases of Oral Mucositis

• Grade-specific Incident Cases of Oral Mucositis

• Gender-specific Incident Cases of Oral Mucositis

• Total Treated Cases of Oral Mucositis

Scope of the Oral Mucositis Market Report

• Therapeutic Assessment: Oral Mucositis current marketed and emerging therapies

• Oral Mucositis Market Dynamics: Key Market Forecast Assumptions of Emerging Oral Mucositis Drugs and Market Outlook

• Key Companies: OncoZenge, EpicentRx, Soligenix, 6S Pharma, Camurus, Amgen, Swedish Orphan Biovitrum, Access Pharmaceuticals, Aurora BioScience, and others

• Key Therapies: BupiZenge, Nibrozetone (RRx-001), Dusquetide (SGX942), 6SP-001, KEPIVANCE (palifermin), EPISIL, MuGard, and others

• Competitive Intelligence Analysis: SWOT analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, Oral Mucositis Market Access and Reimbursement

To know more about Oral Mucositis companies working in the treatment market, visit @ Oral Mucositis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Oral Mucositis Market Report Introduction

2. Executive Summary for Oral Mucositis

3. SWOT Analysis of Oral Mucositis

4. Oral Mucositis Patient Share (%) Overview at a Glance

5. Oral Mucositis Market Overview at a Glance

6. Oral Mucositis Background and Overview

7. Oral Mucositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Oral Mucositis

9. Oral Mucositis Current Treatment and Medical Practices

10. Oral Mucositis Unmet Needs

11. Oral Mucositis Emerging Therapies

12. Oral Mucositis Market Outlook

13. Country-Wise Oral Mucositis Market Analysis (2022–2036)

14. Oral Mucositis Market Access and Reimbursement of Therapies

15. Oral Mucositis Market Drivers

16. Oral Mucositis Market Barriers

17. Oral Mucositis Appendix

18. Oral Mucositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/